New hope for advanced breast cancer patients who stopped responding to earlier therapies
NCT ID NCT07299825
First seen Jan 06, 2026 · Last updated Jun 13, 2026 · Updated 22 times
Summary
This study tests a new drug called A166 in people with HER2-positive breast cancer that has spread and no longer responds to certain previous treatments. About 40 adults aged 18 to 75 will receive A166 to see if it shrinks tumors or slows the disease. The goal is to find a better option for patients who have run out of effective therapies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER-2 POSITIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Henan Provincial Cancer Hospital
RECRUITINGZhenzhou, Henan, 450000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.